$BLUE Form 8-K

0
519

Form 8-K for BLUEBIRD BIO, INC.


8-Sep-2016

Other Events, Financial Statements and Exhibits

Item 8.01 Other EventsOn September 8, 2016, bluebird bio, Inc. (“bluebird”) issued a press release announcing the opening of the Phase 3 HGB-207 clinical trial of its LentiGlobin product candidate in patients with transfusion-dependent beta-thalassemia. The full text of bluebird’s press release regarding this announcement is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

 

Item 9.01 Financial Statements and Exhibits.(d) Exhibits

Exhibit No. Description
99.1 Press release issued by bluebird bio, Inc. on September 8, 2016.


 

LEAVE A REPLY

Please enter your comment!
Please enter your name here